Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.
The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.
The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.
Publications found:
167
Sort by:
Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment
US$ 2,000.00
... barriers that Biosimilar players should be aware. The report – “Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment” looks into several aspects of potential ... their impact on Market Opportunity Global Regulatory Process and Hurdles Risk/Reward profile of developing Herceptin biosimilar
October 2012
70 pages
India Biosimilar Market Analysis
US$ 1,000.00
... 4 insulin biosimilars available in the Indian market. The acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched. “India Biosimilar Market Analysis” research report by KuicK research gives detailed insight on various aspects related the biosimilar market in India like Market Overview, Biosimilar Pipeline Analysis, Biosimilar Development Capabilities ...
August 2012
80 pages
Global Biosimilars Market Report: 2012 Edition
US$ 800.00
... lower return on investments continues to challenge the attractiveness of the biosimilars market. The report analyzes the global biosimilars market. The various drivers and challenges faced by the ...
June 2012
40 pages
EPO Biosimilars Market Forecast to 2015
US$ 300.00
The biosimilars industry has been growing stupendously across the globe for the past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivi...
April 2012
34 pages
G-CSF Biosimilars Market Forecast to 2015
US$ 300.00
For the past few years, the biosimilars industry has been growing stupendously across the globe due to increasing healthcare costs and rising aging population. It is expected to evolve, to a great ext...
April 2012
35 pages
HGH Biosimilars Market Forecast to 2015
US$ 300.00
Across the globe, the biosimilars industry has been growing stupendously for the past few years. Increasing healthcare costs and rising aging population are driving the industry that is expected to ev...
April 2012
35 pages
Merck - Celltrion filed first mAB Biosimilar in Europe: Remicade Challenged
US$ 90.00
Celltrion filed infliximab biosimilar (CT-P13) in Europe and was accepted for review by EMA. It is the first biosimilar mAb to be filed for approval in Europe. The patent ... Celltrion conducted PhI and PhIII clinical trials with the duration of 12 months in more than 850 patients. It has already filed Infliximab ...
April 2012
1 pages
Global Biosimilars Market Forecast to 2015
US$ 1,500.00
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid po...
February 2012
140 pages
Global Biosimilars Market Analysis
US$ 1,400.00
Single User PDF Format: US$ 1,400.00
Multi-User License: US$ 1,800.00
Hard Copy: US$ 1,500.00
CD-ROM: US$ 1,500.00 The global biosimilars industry has been growing stupendously since t...
July 2011
65 pages
Biosimilars Update
US$ 695.00
From Canada and the US to Japan, the EU and Australia, regulators around the world are establishing guidelines that will pave the way for competition between biosimilars and costly biologics. For many...
April 2011
140 pages
Biosimilars Regulatory Update: an Evolving Landscape
US$ 395.00
They’re costly to develop, fraught with potential patient safety concerns and subject to regulations that have yet to be written. Yet for the pharmaceutical industry, biosimilar monoclonal antibodies...
February 2011
59 pages
Biosimilars: Surveying the Market Landscape
US$ 395.00
Worldwide, the story is the same. Governments want cheaper drugs for their populations, while the number and kinds of diseases affecting them continue to evolve and grow. Since 1976, when Genentech be...
October 2010
75 pages
Biosimilars: Market Research Report
US$ 3,950.00
This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for US, Europe, and Japan. ... , Shantha Biotechnics Ltd., Teva Pharmaceutical Industries Ltd., and Wockhardt Ltd. Market data and analytics are derived from primary and secondary ...
April 2010
390 pages
Biosimilars (2009 - 2014)
US$ 5,650.00
... numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into ... of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly ...
September 2009
189 pages
